Panbela Therapeutics, Inc. (PBLA)

OTCMKTS: PBLA · Delayed Price · USD
0.670
-0.005 (-0.71%)
Mar 28, 2024, 3:58 PM EDT - Market closed

Company Description

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs.

The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase.

It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin.

The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020.

Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Panbela Therapeutics, Inc.
Panbela Therapeutics logo
Country United States
Founded 2011
Industry Biotechnology
Sector Healthcare
Employees 6
CEO Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.

Contact Details

Address:
712 Vista Blvd #305
Waconia, Minnesota 55387
United States
Phone (952) 479-1196
Website panbela.com

Stock Details

Ticker Symbol PBLA
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001029125
CUSIP Number 69833W107
ISIN Number US69833W4042
Employer ID 87-0543922
SIC Code 2834

Key Executives

Name Position
Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D. Chief Executive Officer, President and Director
Susan Horvath Vice President of Finance, Chief Financial Officer, Secretary and Treasurer
Tammy Groene Vice President of Operations
Dr. Elizabeth Bruckheimer Ph.D. Vice President and Chief Scientific Officer

Latest SEC Filings

Date Type Title
Mar 26, 2024 10-K Annual Report
Mar 26, 2024 8-K Current Report
Mar 25, 2024 PRE 14A Other preliminary proxy statements
Mar 7, 2024 8-K Current Report
Feb 15, 2024 8-K Current Report
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 8-K Current Report
Feb 1, 2024 8-K Current Report
Jan 30, 2024 424B4 Prospectus
Jan 29, 2024 8-K Current Report